Lapas attēli
PDF
ePub

APPENDIX B

[Submitted with Statement of Lewis A. Engman, President,
Pharmaceutical Manufacturers Association, Before the Committee
on the Judiciary, United States Senate on S.255, the "Patent
Term Restoration Act of 1981 (April 30, 1981:)]

The Time Factor In New Drug Development

Even after a new drug has been discovered, it takes 7-10 years to develop it and get it approved for sale.

[merged small][merged small][merged small][merged small][graphic][subsumed][subsumed][merged small][subsumed][merged small][merged small]

[Submitted with Statement of Lewis A. Engman, President,
Pharmaceutical Manufacturers Association, Before the Committee
on the Judiciary, United States Senate on S.255, the "Patent
Term Restoration Act of 1981" (April 30, 1981):]

[ocr errors]

Declining Patent Protection

These 7-10 years are, in effect, deducted from a drug's patent life. Thus, instead of having 17 years in which to recover its investment like firms in most other industries, the pharmaceutical innovator has only about half that time.

[merged small][subsumed][merged small][graphic][subsumed][subsumed][subsumed][subsumed][subsumed][subsumed][merged small][merged small]

[Submitted with Statement of Mark Novitch, M.D., Deputy Commissioner, Food and Drug Administration, Office of Assistant Secretary for Health and Human Services Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, on H.R. 3605 (a 1-page bill to establish an ANDA procedure for post-1962 drugs) (July 25, 1983:)]

PROTECTION FOR POST-62 DROG PRODUCTS

first time. Approximately 205 of these products are considered products

remaining post-1942 approved products are not considered ANDA candidatas
The product is: (1) an antibiotic and

is covered under the "form 6° procedures; (2) in a class of products not

sodical devices, ens., (3) no longer særksted (either FDA has withdrawa

1982, FDA estimates that mother 40-50 products were approved which would

relevant process or use patents may extend patent protection.

a sumber of these products had no, or very little, patent protestion

For the 205 drug products approved between 1962-1978, 15 products or percent of the drugs had no effective patant life at the time of

approval.

Another 36 products, or 18 percent, had comparatively little

[merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][ocr errors][merged small]

Present data for these drug entities were obtained from the following

sources:

1. The Merek Index, Ninth Mition, Published by Merck & Co.

[ocr errors]

1976 Basic Patents for Major Drugg, Noyes Development Co.,
1969.

3. The U.S. Generic Drag Market, Frost & Sullivan, 1976 and 1980.

S.

Innovation in the Pharmaceutical Industry, David Schwartzman,
The Johns šopkins University Press, 1976.

Dr. Martin Eleman, Center for the Study of Drug Development,
University of Rochester, School of Medicine and Dentistry,
Rochester, M.Y.

6. Telephone queries with individual drug sponsors.

[blocks in formation]

"Old Chemicals"/Patents Expired Before Approval Date (12)

[merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][ocr errors][merged small][merged small][merged small][ocr errors][merged small][merged small][ocr errors][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small][merged small]

1978, 205 products were approved during this time period.

expiration data of "chemical" or "product" patant only; does not cover "use" or "process" patents.

« iepriekšējāTurpināt »